JA

Profile

Research

Social

Other

Narazaki Masashi

楢﨑 雅司

Graduate School of Medicine, Specially Appointed Professor

keyword Clinical immunology,Autoimmune disease,Rheumatoid arthritis,JAK,IL-6,Cytokine

Education

  • 1990/04 - 1994/03, Osaka University
  • 1981/04 - 1987/03, Osaka University, Faculty of Medicine

Research History

  • 2019/05 - Present, 大阪大学大学院医学系研究科, 先端免疫臨床応用学, 特任教授
  • 2014/04 - 2019/04, 大阪大学大学院医学系研究科, 呼吸器・免疫内科学, 講師
  • 2007/09 - 2014/03, 大阪大学大学院医学系研究科, 呼吸器・免疫内科学, 助教
  • 2005/04 - 2007/08, National Cancer Institute/NIH, Staff Scientist
  • 2002/04 - 2005/03, National Cancer Institute/NIH, Research Fellow
  • 1999/04 - 2002/03, 大阪大学医学部附属病院, 医員
  • 1994/04 - 1997/03, 日本学術振興会, 特別研究員
  • 1988/04 - 1990/03, 国立大阪南病院, 研修医
  • 1987 - 1988, 大阪大学医学部附属病院, 研修医

Research Areas

  • Life sciences, Allergies and connective tissue disease

Professional Memberships

  • 日本内科学会
  • 日本臨床免疫学会
  • 日本免疫学会
  • 日本アレルギー学会
  • 日本リウマチ学会

Papers

  • Historical overview of the interleukin-6 family cytokine, Sujin Kang,Masashi Narazaki,Hozaifa Metwally,Tadamitsu Kishimoto, Journal of Experimental Medicine, Rockefeller University Press, Vol. 217, No. 5, 2020/05/04
  • Targeting Interleukin-6 Signaling in Clinic., Kang S,Tanaka T,Narazaki M,Kishimoto T, Immunity, Vol. 50, No. 4, p. 1007-1023, 2019/04
  • The two-faced cytokine IL-6 in host defense and diseases, Narazaki M,Kishimoto T, Int J Mol Sci, 2018/11
  • Interleukin (IL-6) Immunotherapy, Toshio Tanaka,Masashi Narazaki,Tadamitsu Kishimoto, Cold Spring Harbor Perspectives in Biology, Cold Spring Harbor Laboratory, Vol. 10, No. 8, p. a028456-a028456, 2018/08
  • The role and therapeutic targeting of IL-6 in rheumatoid arthritis, Masashi Narazaki,Toshio Tanaka,Tadamitsu Kishimoto, Expert Review of Clinical Immunology, Informa UK Limited, Vol. 13, No. 6, p. 535-551, 2017/06/03
  • Immunotherapeutic implications of IL-6 blockade for cytokine storm, Toshio Tanaka,Masashi Narazaki,Tadamitsu Kishimoto, Immunotherapy, Future Medicine Ltd, Vol. 8, No. 8, p. 959-970, 2016/07
  • IL-6 in Inflammation, Immunity, and Disease, T. Tanaka,M. Narazaki,T. Kishimoto, Cold Spring Harbor Perspectives in Biology, Cold Spring Harbor Laboratory, Vol. 6, No. 10, p. a016295-a016295, 2014/10/01
  • Therapeutic Targeting of the Interleukin-6 Receptor, Toshio Tanaka,Masashi Narazaki,Tadamitsu Kishimoto, Annual Review of Pharmacology and Toxicology, Annual Reviews, Vol. 52, No. 1, p. 199-219, 2012/02/10
  • Therapeutic effect of tocilizumab on two patients with polymyositis, M. Narazaki,K. Hagihara,Y. Shima,A. Ogata,T. Kishimoto,T. Tanaka, Rheumatology, Oxford University Press (OUP), Vol. 50, No. 7, p. 1344-1346, 2011/07/01
  • Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis, Masashi Narazaki,Marta Segarra,Xu Hou,Toshio Tanaka,Xuri Li,Giovanna Tosato, Blood, American Society of Hematology, Vol. 116, No. 16, p. 3099-3107, 2010/10/21
  • Sulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3A, Masashi Narazaki,Marta Segarra,Giovanna Tosato, Blood, American Society of Hematology, Vol. 111, No. 8, p. 4126-4136, 2008/04/15
  • Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A, Masashi Narazaki,Giovanna Tosato, Blood, American Society of Hematology, Vol. 107, No. 10, p. 3892-3901, 2006/05/15
  • Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus, Y Aoki,M Narazaki,T Kishimoto,G Tosato, BLOOD, AMER SOC HEMATOLOGY, Vol. 98, No. 10, p. 3042-3049, 2001/11
  • Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells, A Yokota,M Narazaki,Y Shima,N Murata,T Tanaka,M Suemura,K Yoshizaki,H Fujiwara,Tsuyuguchi, I,T Kishimoto, JOURNAL OF RHEUMATOLOGY, J RHEUMATOL PUBL CO, Vol. 28, No. 9, p. 1952-1959, 2001/09
  • Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling, M. Narazaki,M. Fujimoto,T. Matsumoto,Y. Morita,H. Saito,T. Kajita,K. Yoshizaki,T. Naka,T. Kishimoto, Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, Vol. 95, No. 22, p. 13130-13134, 1998/10/27
  • Structure and function of a new STAT-induced STAT inhibitor, Tetsuji Naka,Masashi Narazaki,Moritoshi Hirata,Tomoshige Matsumoto,Seijiro Minamoto,Atsufumi Aono,Norihiro Nishimoto,Tadahiro Kajita,Tetsuya Taga,Kazuyuki Yoshizaki,Shizuo Akira,Tadamitsu Kishimoto, Nature, Springer Science and Business Media LLC, Vol. 387, No. 6636, p. 924-929, 1997/06
  • Interleukin-6 family of cytokines and gp130, T. Kishimoto,S. Akira,M. Narazaki,T. Taga, Blood, Vol. 86, No. 4, p. 1243-1254, 1995
  • Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130., M. Narazaki,B. A. Witthuhn,K. Yoshida,O. Silvennoinen,K. Yasukawa,J. N. Ihle,T. Kishimoto,T. Taga, Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, Vol. 91, No. 6, p. 2285-2289, 1994/03/15
  • Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130, Narazaki M,Yasukawa K,Saito T,Ohsugi Y,Fukui H,Koishihara Y,Yancopoulos GD,Taga T,Kishimoto T, BLOOD, W B SAUNDERS CO, Vol. 82, No. 4, p. 1120-1126, 1993/08
  • Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130., T. Taga,M. Narazaki,K. Yasukawa,T. Saito,D. Miki,M. Hamaguchi,S. Davis,M. Shoyab,G. D. Yancopoulos,T. Kishimoto, Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, Vol. 89, No. 22, p. 10998-11001, 1992/11/15
  • Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family., M. Murakami,M. Narazaki,M. Hibi,H. Yawata,K. Yasukawa,M. Hamaguchi,T. Taga,T. Kishimoto, Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, Vol. 88, No. 24, p. 11349-11353, 1991/12/15
  • Tet DNA demethylase is required for plasma cell differentiation by controlling expression levels of IRF4., Fujii K,Tanaka S,Hasegawa T,Narazaki M,Kumanogoh A,Koseki H,Kurosaki T,Ise W, Int Immunol., Vol. 32, No. 10, p. 683-690, 2020/09
  • Increased levels of plasma nucleotides in patients with rheumatoid arthritis, Toshihiro Kishikawa,Yuichi Maeda,Takuro Nii,Noriko Arase,Jun Hirata,Ken Suzuki,Kenichi Yamamoto,Tatsuo Masuda,Kotaro Ogawa,Shigeyoshi Tsuji,Masato Matsushita,Hidetoshi Matsuoka,Maiko Yoshimura,Shinichiro Tsunoda,Shiro Ohshima,Masashi Narazaki,Atsushi Ogata,Yukihiko Saeki,Hidenori Inohara,Atsushi Kumanogoh,Kiyoshi Takeda,Yukinori Okada, International Immunology, Oxford University Press (OUP), 2020/08/31
  • A case of SAPHO syndrome with the lesions limited to the skull., Oguro E,Kato Y,Takamatsu H,Narazaki M,Kumanogoh A, Rheumatol Adv Pract., Vol. 4, No. 2, 2020/07
  • Pristane/Hypoxia (PriHx) Mouse as a Novel Model of Pulmonary Hypertension Reflecting Inflammation and Fibrosis, Hiroyoshi Mori,Tomohiko Ishibashi,Tadakatsu Inagaki,Makoto Okazawa,Takeshi Masaki,Ryotaro Asano,Yusuke Manabe,Keiko Ohta-Ogo,Masashi Narazaki,Hatsue Ishibashi-Ueda,Atsushi Kumanogoh,Yoshikazu Nakaoka, Circulation Journal, Japanese Circulation Society, Vol. 84, No. 7, p. 1163-1172, 2020/06/25
  • Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review., Yuta Yamaguchi,Yuichi Maeda,Takayuki Shibahara,Shinichiro Nameki,Akihiko Nakabayashi,Kiyohide Komuta,Yumiko Mizuno,Mayu Yagita,Yusuke Manabe,Takayoshi Morita,Masayuki Nishide,Akane Watanabe,Hyota Takamatsu,Sumiyuki Nishida,Toru Hirano,Yoshihito Shima,Masashi Narazaki,Atsushi Kumanogoh, Modern Rheumatology Case Reports, 2020/02
  • Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population., Toshihiro Kishikawa,Yuichi Maeda,Takuro Nii,Daisuke Motooka,Yuki Matsumoto,Masato Matsushita,Hidetoshi Matsuoka,Maiko Yoshimura,Shoji Kawada,Satoru Teshigawara,Eri Oguro,Yasutaka Okita,Keisuke Kawamoto,Shinji Higa,Toru Hirano,Masashi Narazaki,Atsushi Ogata,Yukihiko Saeki,Shota Nakamura,Hidenori Inohara,Atsushi Kumanogoh,Kiyoshi Takeda,Yukinori Okada, Annals of the rheumatic diseases, Vol. 79, No. 1, p. 103-111, 2020/01
  • The COMMD3/8 complex determines GRK6 specificity for chemoattractant receptors., Akiko Nakai,Jun Fujimoto,Haruhiko Miyata,Ralf Stumm,Masashi Narazaki,Stefan Schulz,Yoshihiro Baba,Atsushi Kumanogoh,Kazuhiro Suzuki, The Journal of experimental medicine, Vol. 216, No. 7, p. 1630-1647, 2019/07/01
  • Anti-receptor activator of nuclear factor κB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis., Takayoshi Morita,Yoshihito Shima,Kosuke Fujimoto,Hideki Tsuboi,Yukihiko Saeki,Masashi Narazaki,Atsushi Ogata,Atsushi Kumanogoh, International immunology, Vol. 31, No. 5, p. 277-285, 2019/04/26
  • Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus., Yasuhiro Kato,JeongHoon Park,Hyota Takamatsu,Hachirou Konaka,Wataru Aoki,Syunsuke Aburaya,Mitsuyoshi Ueda,Masayuki Nishide,Shohei Koyama,Yoshitomo Hayama,Yuhei Kinehara,Toru Hirano,Yoshihito Shima,Masashi Narazaki,Atsushi Kumanogoh, Annals of the rheumatic diseases, Vol. 77, No. 10, p. 1507-1515, 2018/10
  • Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus, Shuhei Sakakibara,Takao Arimori,Kazuo Yamashita,Hideyuki Jinzai,Daisuke Motooka,Shota Nakamura,Songling Li,Kazuya Takeda,Jun Katayama,Marwa Ali El Hussien,Masashi Narazaki,Toshio Tanaka,Daron M. Standley,Junichi Takagi,Hitoshi Kikutani, Scientific Reports, Springer Science and Business Media LLC, Vol. 7, No. 1, 2017/12
  • Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish., Tanaka T,Narazaki M, Journal of Scleroderma and Related Disorders, SAGE Publications, Vol. 2, No. 2 suppl, p. S20-S28, 2017/08
  • Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis, Masayuki Nishide,Satoshi Nojima,Daisuke Ito,Hyota Takamatsu,Shohei Koyama,Sujin Kang,Tetsuya Kimura,Keiko Morimoto,Takashi Hosokawa,Yoshitomo Hayama,Yuhei Kinehara,Yasuhiro Kato,Takeshi Nakatani,Yoshimitsu Nakanishi,Takeshi Tsuda,Jeong Hoon Park,Toru Hirano,Yoshihito Shima,Masashi Narazaki,Eiichi Morii,Atsushi Kumanogoh, Annals of the Rheumatic Diseases, BMJ, Vol. 76, No. 8, p. 1440-1448, 2017/08
  • Regulation of intestinal homeostasis by the ulcerative colitis-associated gene RNF186, Kosuke Fujimoto,Makoto Kinoshita,Hiroo Tanaka,Daisuke Okuzaki,Yosuke Shimada,Hisako Kayama,Ryu Okumura,Yoki Furuta,Masashi Narazaki,Atsushi Tamura,Shigetsugu Hatakeyama,Masahito Ikawa,Kiichiro Tsuchiya,Mamoru Watanabe,Atsushi Kumanogoh,Sachiko Tsukita,Kiyoshi Takeda, Mucosal Immunology, Springer Science and Business Media LLC, Vol. 10, No. 2, p. 446-459, 2017/03
  • Fungal ITS1 Deep-Sequencing Strategies to Reconstruct the Composition of a 26-Species Community and Evaluation of the Gut Mycobiota of Healthy Japanese Individuals, Daisuke Motooka,Kosuke Fujimoto,Reiko Tanaka,Takashi Yaguchi,Kazuyoshi Gotoh,Yuichi Maeda,Yoki Furuta,Takashi Kurakawa,Naohisa Goto,Teruo Yasunaga,Masashi Narazaki,Atsushi Kumanogoh,Toshihiro Horii,Tetsuya Iida,Kiyoshi Takeda,Shota Nakamura, Frontiers in Microbiology, Frontiers Media SA, Vol. 8, 2017/02/15
  • Structural basis of antigen recognition by anti-dsDNA antibodies isolated from systemic lupus erythematosus patients, Shuhei Sakakibara,Kazuya Takeda,Masashi Narazaki,Toshio Tanaka,Hitoshi Kikutani, 2016/12
  • Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine, Yuichi Maeda,Takashi Kurakawa,Eiji Umemoto,Daisuke Motooka,Yoshinaga Ito,Kazuyoshi Gotoh,Keiji Hirota,Masato Matsushita,Yoki Furuta,Masashi Narazaki,Noriko Sakaguchi,Hisako Kayama,Shota Nakamura,Tetsuya Iida,Yukihiko Saeki,Atsushi Kumanogoh,Shimon Sakaguchi,Kiyoshi Takeda, Arthritis & Rheumatology, Wiley, Vol. 68, No. 11, p. 2646-2661, 2016/11
  • The Analysis of Severity of Arthritis in the Intestinal Microbiota-Humanized Mice, Yuichi Maeda,Masato Matsushita,Masashi Narazaki,Yukihiko Saeki,Atsushi Kumanogoh,Kiyoshi Takeda, ARTHRITIS & RHEUMATOLOGY, WILEY, Vol. 68, 2016/10
  • Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis, Yuhsuke Ohmi,Wataru Ise,Akira Harazono,Daisuke Takakura,Hidehiro Fukuyama,Yoshihiro Baba,Masashi Narazaki,Hirofumi Shoda,Nobunori Takahashi,Yuki Ohkawa,Shuting Ji,Fumihiro Sugiyama,Keishi Fujio,Atsushi Kumanogoh,Kazuhiko Yamamoto,Nana Kawasaki,Tomohiro Kurosaki,Yoshimasa Takahashi,Koichi Furukawa, Nature Communications, Springer Science and Business Media LLC, Vol. 7, No. 1, 2016/09
  • LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF-κB activation, Keiko Morimoto,Yoshihiro Baba,Hisaaki Shinohara,Sujin Kang,Satoshi Nojima,Tetsuya Kimura,Daisuke Ito,Yuji Yoshida,Yohei Maeda,Hana Sarashina-Kida,Masayuki Nishide,Takashi Hosokawa,Yasuhiro Kato,Yoshitomo Hayama,Yuhei Kinehara,Tatsusada Okuno,Hyota Takamatsu,Toru Hirano,Yoshihito Shima,Masashi Narazaki,Tomohiro Kurosaki,Toshihiko Toyofuku,Atsushi Kumanogoh, Scientific Reports, Springer Science and Business Media LLC, Vol. 6, No. 1, 2016/05
  • Regulation of IL-6 in Immunity and Diseases, Toshio Tanaka,Masashi Narazaki,Kazuya Masuda,Tadamitsu Kishimoto, Advances in Experimental Medicine and Biology, Springer Netherlands, p. 79-88, 2016
  • Antigen-specific maturation of anti-nuclear antibodies in systemic lupus erythematosus, Shuhei Sakakibara,Kazuya Takeda,Teruhito Yasui,Masashi Narazaki,Toshio Tanaka,Hitoshi Kikutani, 2015/11
  • Optimization of Treatment Intervals of Tocilizumab and Golimumab By Measuring Serum Trough Levels in Rheumatoid Arthritis Patients, Yoshinobu Matsuura,Masashi Narazaki,Masayuki Nishide,Yasuhiro Kato,Hideki Yorifuji,Toru Hirano,Yoshihito Shima,Toshio Tanaka,Atsushi Ogata,Atsushi Kumanogoh, ARTHRITIS & RHEUMATOLOGY, WILEY-BLACKWELL, Vol. 67, p. 815-816, 2015/10
  • Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications, Yuji Yoshida,Atsushi Ogata,Sujin Kang,Kousuke Ebina,Kenrin Shi,Satoshi Nojima,Tetsuya Kimura,Daisuke Ito,Keiko Morimoto,Masayuki Nishide,Takashi Hosokawa,Toru Hirano,Yoshihito Shima,Masashi Narazaki,Hideki Tsuboi,Yukihiko Saeki,Tetsuya Tomita,Toshio Tanaka,Atsushi Kumanogoh, Arthritis & Rheumatology, Wiley, Vol. 67, No. 6, p. 1481-1490, 2015/06
  • Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab, Yoshihito Shima,Naoki Hosen,Toru Hirano,Junsuke Arimitsu,Sumiyuki Nishida,Keisuke Hagihara,Masashi Narazaki,Atsushi Ogata,Toshio Tanaka,Tadamitsu Kishimoto,Atsushi Kumanogoh, Modern Rheumatology, Informa UK Limited, Vol. 25, No. 1, p. 134-137, 2015/01/02
  • Tocilizumab Increases Serum Adiponectin and Reduces Serum Fatty Acid Binding Protein 4 in Patients With Rheumatoid Arthritis., Urushima H,Sanada Y,Ogata A,Yoshida M,Lin H,Hagihara K,Narazaki M,Tanaka T,Ito T,Maeda K, Journal of Endocrinology and Metabolism, Vol. 4, No. 5, p. 143-147, 2015/01
  • INCREASED SOLUBLE SEMAPHORIN 4D IN RHEUMATOID ARTHRITIS, Y. Yoshida,A. Ogata,T. Tomita,S. Kang,T. Hirano,Y. Shima,M. Narazaki,T. Tanaka,A. Kumanogoh, ANNALS OF THE RHEUMATIC DISEASES, BMJ PUBLISHING GROUP, Vol. 73, p. 854-855, 2014/06
  • A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy, Toshio Tanaka,Masashi Narazaki,Atsushi Ogata,Tadamitsu Kishimoto, Seminars in Immunology, Elsevier BV, Vol. 26, No. 1, p. 88-96, 2014/02
  • Immune reconstitution inflammatory syndrome in a patient with adult-onset Still's disease: Graft-versus-host-like skin reaction with possible asymptomatic human herpes virus reactivation during steroid tapering, Kosuke Yamaga,Takaaki Hanafusa,Hiroaki Azukizawa,Atsushi Tanemura,Takuro Nii,Masayuki Nishide,Masashi Narazaki,Ichiro Katayama, European Journal of Dermatology, John Libbey Eurotext, Vol. 24, No. 1, p. 101-103, 2014/01
  • Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis, Y Hishitani,A Ogata,Y Shima,T Hirano,K Ebina,Y Kunugiza,K Shi,M Narazaki,K Hagihara,T Tomita,H Yoshikawa,T Tanaka,A Kumanogoh, Scandinavian Journal of Rheumatology, Informa UK Limited, Vol. 42, No. 4, p. 253-259, 2013/08
  • Tocilizumab: An updated review of its use in the treatment of rheumatoid arthritis and its application for other immune-Mediated diseases, Toshio Tanaka,Atsushi Ogata,Masashi Narazaki, Clinical Medicine Insights: Therapeutics, Vol. 5, p. 33-52, 2013
  • Comparison of Tolerability Between Tumor Necrosis Factor-Inhibitors and Tocilizumab for the Treatment of Rheumatoid Arthritis, Yoshihiro Hishitani,Yoshihito Shima,Toru Hirano,Keisuke Hagihara,Kosuke Ebina,Yasuo Kunugiza,Kenrin Shi,Masashi Narazaki,Atsushi Ogata,Tetsuya Tomita,Toshio Tanaka,Atsushi Kumanogoh, ARTHRITIS AND RHEUMATISM, WILEY-BLACKWELL, Vol. 64, No. 10, p. S219-S220, 2012/10
  • A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab, Toru Hirano,Nobuyuki Ohguro,Satoshi Hohki,Keisuke Hagihara,Yoshihito Shima,Masashi Narazaki,Atsushi Ogata,Kazuyuki Yoshizaki,Atsushi Kumanogoh,Tadamitsu Kishimoto,Toshio Tanaka, Modern Rheumatology, Vol. 22, No. 2, p. 298-302, 2012/04
  • Therapeutic implications of tocilizumab, a humanized anti-interleukin-6 receptor antibody, for various immune-mediated diseases: An update review, Toshio Tanaka,Atsushi Ogata,Yoshihito Shima,Masashi Narazaki,Atsushi Kumanogoh,Tadamitsu Kishimoto, Current Rheumatology Reviews, Bentham Science Publishers B.V., Vol. 8, No. 3, p. 209-226, 2012
  • Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders, Toshio Tanaka,Keisuke Hagihara,Yoshihito Shima,Masashi Narazaki,Atsushi Ogata,Atsushi Kumanogoh, DRUG DEVELOPMENT RESEARCH, WILEY, Vol. 72, No. 8, p. 717-732, 2011/12
  • Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases, Toshio Tanaka,Masashi Narazaki,Tadamitsu Kishimoto, FEBS Letters, Wiley, Vol. 585, No. 23, p. 3699-3709, 2011/12/01
  • Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab, Sumiyuki Nishida,Tomio Kawasaki,Hirokazu Kashiwagi,Atsuyoshi Morishima,Yoshihiro Hishitani,Mari Kawai,Toru Hirano,Taeko Ishii,Keisuke Hagihara,Yoshihito Shima,Masashi Narazaki,Atsushi Ogata,Yoshihiro Oka,Tadamitsu Kishimoto,Toshio Tanaka, MODERN RHEUMATOLOGY, SPRINGER, Vol. 21, No. 4, p. 420-422, 2011/08
  • Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab: Figure 1, Atsushi Ogata,Atsuyoshi Morishima,Toru Hirano,Yoshihiro Hishitani,Keisuke Hagihara,Yoshihito Shima,Masashi Narazaki,Toshio Tanaka, Annals of the Rheumatic Diseases, BMJ, Vol. 70, No. 6, p. 1164-1165, 2011/06
  • The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab, Y. Shima,Y. Kuwahara,H. Murota,S. Kitaba,M. Kawai,T. Hirano,J. Arimitsu,M. Narazaki,K. Hagihara,A. Ogata,I. Katayama,I. Kawase,T. Kishimoto,T. Tanaka, Rheumatology, Oxford University Press (OUP), Vol. 49, No. 12, p. 2408-2412, 2010/12/01
  • Tocilizumab for the treatment of rheumatoid arthritis, Toshio Tanaka,Atsushi Ogata,Masashi Narazaki, Expert Review of Clinical Immunology, Informa UK Limited, Vol. 6, No. 6, p. 843-854, 2010/11
  • Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab, T. Tanaka,K. Hagihara,Y. Shima,M. Narazaki,A. Ogata,I. Kawase,T. Kishimoto, Rheumatology, Oxford University Press (OUP), Vol. 49, No. 4, p. 824-826, 2010/04/01
  • Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens, Atsushi Ogata,Masahide Mori,Shoji Hashimoto,Yukihiro Yano,Takeya Fujikawa,Mari Kawai,Yusuke Kuwahara,Toru Hirano,Junsuke Arimitsu,Keisuke Hagihara,Yoshihito Shima,Masashi Narazaki,Souichirou Yokota,Tadamitsu Kishimoto,Ichiro Kawase,Toshio Tanaka, MODERN RHEUMATOLOGY, TAYLOR & FRANCIS LTD, Vol. 20, No. 2, p. 130-133, 2010/04
  • Successful treatment of reactive arthritis with a humanized anti–interleukin-6 receptor antibody, tocilizumab, Toshio Tanaka,Yusuke Kuwahara,Yoshihito Shima,Toru Hirano,Mari Kawai,Masako Ogawa,Junsuke Arimitsu,Keisuke Hagihara,Masashi Narazaki,Atsushi Ogata,Ichiro Kawase,Tadamitsu Kishimoto, Arthritis & Rheumatism, Wiley, Vol. 61, No. 12, p. 1762-1764, 2009/12/15
  • Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway, Fumitaka Terabe,Masayasu Kitano,Mari Kawai,Yusuke Kuwahara,Toru Hirano,Junsuke Arimitsu,Keisuke Hagihara,Yoshihito Shima,Masashi Narazaki,Toshio Tanaka,Ichiro Kawase,Hajime Sano,Atsushi Ogata, MODERN RHEUMATOLOGY, SPRINGER, Vol. 19, No. 5, p. 522-529, 2009/10
  • Preventative Effect of a Flavonoid, Enzymatically Modified Isoquercitrin on Ocular Symptoms of Japanese Cedar Pollinosis, Toru Hirano,Mari Kawai,Junsuke Arimitsu,Masako Ogawa,Yusuke Kuwahara,Keisuke Hagihara,Yoshihito Shima,Masashi Narazaki,Atsushi Ogata,Mihoko Koyanagi,Tomoko Kai,Ryosuke Shimizu,Masamitsu Moriwaki,Yukio Suzuki,Satoshi Ogino,Ichiro Kawase,Toshio Tanaka, Allergology International, Japanese Society of Allergology, Vol. 58, No. 3, p. 373-382, 2009/09
  • Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment, S Nishida,K Hagihara,Y Shima,M Kawai,Y Kuwahara,J Arimitsu,T Hirano,M Narazaki,A Ogata,K Yoshizaki,I Kawase,T Kishimoto,T Tanaka, Annals of the Rheumatic Diseases, BMJ, Vol. 68, No. 7, p. 1235-1236, 2009/07/01
  • Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis, Atsushi Ogata,Fumitaka Terabe,Kaori Nakanishi,Mari Kawai,Yusuke Kuwahara,Toru Hirano,Jyunsuke Arimitsu,Keisuke Hagihara,Yoshihito Shima,Masashi Narazaki,Toshio Tanaka,Ichiro Kawase, Joint Bone Spine, Elsevier BV, Vol. 76, No. 1, p. 105-107, 2009/01
  • Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis: A Randomized Double-Blind Placebo-Controlled Trial, Mari Kawai,Toru Hirano,Junsuke Arimitsu,Shinji Higa,Yusuke Kuwahara,Keisuke Hagihara,Yoshihito Shima,Masashi Narazaki,Atsushi Ogata,Mihoko Koyanagi,Tomoko Kai,Ryosuke Shimizu,Masamitsu Moriwaki,Yukio Suzuki,Satoshi Ogino,Ichiro Kawase,Toshio Tanaka, International Archives of Allergy and Immunology, S. Karger AG, Vol. 149, No. 4, p. 359-368, 2009
  • Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis, M. Kawai,K. Hagihara,T. Hirano,Y. Shima,Y. Kuwahara,J. Arimitsu,M. Narazaki,A. Ogata,I. Kawase,T. Kishimoto,T. Tanaka, Rheumatology, Oxford University Press (OUP), Vol. 48, No. 3, p. 318-319, 2008/10/17
  • The Molecular Biology of Interleukin 6 and its Receptor, Tadamitsu Kishimoto,Masahiko Hibi,Masaaki Murakami,Masashi Narazaki,Mikiyoshi Saito,Tetsuya Taga, Novartis Foundation Symposia, John Wiley & Sons, Ltd., p. 5-23, 2007/09/28
  • Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1α in the circulation, David A. Davis,Kathleen E. Singer,Maria De La Luz Sierra,Masashi Narazaki,Fuquan Yang,Henry M. Fales,Robert Yarchoan,Giovanna Tosato, Blood, American Society of Hematology, Vol. 105, No. 12, p. 4561-4568, 2005/06/15
  • Differential processing of stromal-derived factor-1α and stromal-derived factor-1β explains functional diversity, Maria De La Luz Sierra,Fuquan Yang,Masashi Narazaki,Ombretta Salvucci,David Davis,Robert Yarchoan,Hongwei H. Zhang,Henry Fales,Giovanna Tosato, Blood, American Society of Hematology, Vol. 103, No. 7, p. 2452-2459, 2004/04/01
  • ステロイド療法中に発症した肺ノカルジア症の一例, 鈴木真優美、楢崎雅司、大島至朗、長谷井仁美、田中敏郎、佐伯行彦、末村正樹、仲哲治, 日本胸部臨床, Vol. 61, p. 820-826, 2002
  • Viral Interleukin 6 Stimulates Human Peripheral Blood B Cells That Are Unresponsive to Human Interleukin 6, Elizabeth C. Breen,Julia R. Gage,Beichu Guo,Larry Magpantay,Masashi Narazaki,Tadamitsu Kishimoto,Steve Miles,Otoniel Martínez-Maza, Cellular Immunology, Elsevier BV, Vol. 212, No. 2, p. 118-125, 2001/09
  • SOCS-1/SSI-1-Deficient NKT Cells Participate in Severe Hepatitis through Dysregulated Cross-Talk Inhibition of IFN-γ and IL-4 Signaling In Vivo, Tetsuji Naka,Hiroko Tsutsui,Minoru Fujimoto,Yoshinori Kawazoe,Hidetsugu Kohzaki,Yoshiaki Morita,Nakagawa,Masashi Narazaki,Keishi Adachi,Tomohiro Yoshimoto,Kenji Nakanishi,Tadamitsu Kishimoto, Immunity, Elsevier BV, Vol. 14, No. 5, p. 535-545, 2001/05
  • Signal Transducer and Activator of Transcription (Stat)-Induced Stat Inhibitor 1 (Ssi-1)/Suppressor of Cytokine Signaling 1 (Socs1) Inhibits Insulin Signal Transduction Pathway through Modulating Insulin Receptor Substrate 1 (Irs-1) Phosphorylation, Yoshinori Kawazoe,Tetsuji Naka,Minoru Fujimoto,Hidetsugu Kohzaki,Yoshiaki Morita,Masashi Narazaki,Kohichi Okumura,Hiroshi Saitoh,Reiko Nakagawa,Yasuo Uchiyama,Shizuo Akira,Tadamitsu Kishimoto, Journal of Experimental Medicine, Rockefeller University Press, Vol. 193, No. 2, p. 263-270, 2001/01/15
  • Defective Thymocyte Development and Perturbed Homeostasis of T cells in STAT-Induced STAT Inhibitor-1/Suppressors of Cytokine Signaling-1 Transgenic Mice, Minoru Fujimoto,Tetsuji Naka,Reiko Nakagawa,Yoshinori Kawazoe,Yoshiaki Morita,Akihiro Tateishi,Koichi Okumura,Masashi Narazaki,Tadamitsu Kishimoto, The Journal of Immunology, The American Association of Immunologists, Vol. 165, No. 4, p. 1799-1806, 2000/08/15
  • IFN Regulatory Factor-1-Mediated Transcriptional Activation of Mouse STAT-Induced STAT Inhibitor-1 Gene Promoter by IFN-γ, Hiroshi Saito,Yoshiaki Morita,Minoru Fujimoto,Masashi Narazaki,Tetsuji Naka,Tadamitsu Kishimoto, The Journal of Immunology, The American Association of Immunologists, Vol. 164, No. 11, p. 5833-5843, 2000/06/01
  • Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha -induced cell death in fibroblasts, Y. Morita,T. Naka,Y. Kawazoe,M. Fujimoto,M. Narazaki,R. Nakagawa,H. Fukuyama,S. Nagata,T. Kishimoto, Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, Vol. 97, No. 10, p. 5405-5410, 2000/05/09
  • Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice, T. Naka,T. Matsumoto,M. Narazaki,M. Fujimoto,Y. Morita,Y. Ohsawa,H. Saito,T. Nagasawa,Y. Uchiyama,T. Kishimoto, Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, Vol. 95, No. 26, p. 15577-15582, 1998/12/22
  • Cloning and Functional Analysis of New Members of STAT Induced STAT Inhibitor (SSI) Family: SSI-2 and SSI-3, Seijiro Minamoto,Kazuhiro Ikegame,Kiyonobu Ueno,Masashi Narazaki,Tetsuji Naka,Hiroyasu Yamamoto,Tomoshige Matsumoto,Hiroshi Saito,Shigeto Hosoe,Tadamitsu Kishimoto, Biochemical and Biophysical Research Communications, Elsevier BV, Vol. 237, No. 1, p. 79-83, 1997/08
  • Leptin receptor (OB-R) oligomerizes with itself but not with its closely related cytokine signal transducer gp130, Kinichi Nakashima,Masashi Narazaki,Tetsuya Taga, FEBS Letters, Wiley, Vol. 403, No. 1, p. 79-82, 1997/02/10
  • Vav is associated with signal transducing molecules gp130, Grb2 and Erk2, and is tyrosine phosphorylated in response to interleukin-6, Ihn-Sook Lee,Yin Liu,Masashi Narazaki,Masahiko Hibi,Tadamitsu Kishimoto,Tetsuya Taga, FEBS Letters, Wiley, Vol. 401, No. 2-3, p. 133-137, 1997/01/20
  • Overlapping and distinct signals through leptin receptor (OB-R) and a closely related cytokine signal transducer, gp130, Kinichi Nakashima,Masashi Narazaki,Tetsuya Taga, FEBS Letters, Wiley, Vol. 401, No. 1, p. 49-52, 1997/01/13
  • Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy, Kai C. Wollert,Tetsuya Taga,Mikiyoshi Saito,Masashi Narazaki,Tadamitsu Kishimoto,Christopher C. Glembotski,Ann B. Vernallis,John K. Heath,Diane Pennica,William I. Wood,Kenneth R. Chien, Journal of Biological Chemistry, American Society for Biochemistry & Molecular Biology (ASBMB), Vol. 271, No. 16, p. 9535-9545, 1996/04/19
  • Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal, Hiroshi Suzuki,Kiyoshi Yasukawa,Takashi Saito,Masashi Narazak,Atsuhiko Hasegawa,Tetsuya Taga,Tadamitsu Kishimoto, European Journal of Immunology, Wiley, Vol. 23, No. 5, p. 1078-1082, 1993/05
  • Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130, K. Yasukawa,K. Futatsugi,T. Saito,H. Yawata,M. Narazaki,H. Suzuki,T. Taga,T. Kishimoto, Immunology Letters, Elsevier BV, Vol. 31, No. 2, p. 123-130, 1992/02
  • INTERLEUKIN-6 RECEPTOR AND SIGNALS, T TAGA,M HIBI,M MURAKAMI,M SAITO,H YAWATA,M NARAZAKI,Y HIRATA,T SUGITA,K YASUKAWA,T HIRANO,T KISHIMOTO, CHEMICAL IMMUNOLOGY, KARGER, Vol. 51, p. 181-204, 1992

Misc.

  • 関節リウマチと自然免疫, 楢崎雅司, 炎症と免疫, Vol. 28, No. 1, p. 62-66, 2020/01
  • IL-6シグナル伝達とその制御, 楢崎雅司, 炎症と免疫, Vol. 27, No. 3, p. 52-56, 2019/05
  • 末梢血好酸球増多の鑑別診断, 楢崎雅司, 診断と治療, Vol. 103, No. 5, p. 571-576, 2015/05
  • 関節リウマチ以外の疾患におけるIL-6阻害薬の有用性, 吉田祐志,楢崎雅司,田中敏郎, リウマチ科, Vol. 47, No. 6, p. 667-673, 2012
  • ステロイドの作用機序・分子構造, 楢崎雅司, 日本医事新報, Vol. 4595, p. 56-57, 2012
  • What kind of durometer is best suited for the assessment of skin disease in systemic sclerosis? Comment on the article by Kissin et al, Yusuke Kuwahara,Yoshihito Shima,Mari Kawai,Keisuke Hagihara,Toru Hirano,Junsuke Arimitsu,Masashi Narazaki,Atsushi Ogata,Toshio Tanaka,Ichiro Kawase,Akira Ogiwara, Arthritis & Rheumatism, Wiley, Vol. 59, No. 4, p. 601-601, 2008/04/15
  • Neuropilin-2: A new molecular target for antiangiogenic and antitumor strategies, Masashi Narazaki,Marta Segarra,Giovanna Tosato, JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIV PRESS INC, Vol. 100, No. 2, p. 81-83, 2008/01
  • Conflicting results from clinical observations and murine models: What is the role of plasminogen activators in tumor growth?, M Narazaki,G Tosato, JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIV PRESS INC, Vol. 98, No. 11, p. 726-727, 2006/06
  • Tumor cell populations differ in angiogenic activity: A model system for spontaneous angiogenic switch can tell us why, M Narazaki,G Tosato, JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIV PRESS INC, Vol. 98, No. 5, p. 294-295, 2006/03
  • Canstatin: An inhibitor of angiogenesis and tumor growth revisited, M Narazaki,G Tosato, CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, Vol. 12, No. 2, p. 110-112, 2006/03
  • Targeting coagulation to the tumor microvasculature: Perspectives and therapeutic implications from preclinical studies, M Narazaki,G Tosato, JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIV PRESS INC, Vol. 97, No. 10, p. 705-707, 2005/05
  • Negative regulation of cytokine signals by STAT-induced STAT-inhibitor-1 (SSI-1), T Kishimoto,M Narazaki,T Matsumoto,T Naka, EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD, Vol. 9, No. 3, p. 294-294, 1998/09
  • Negative regulation of cytokine signals by STAT-induced STAT-inhibitor-1 (SSI-1)., T Kishimoto,M Narazaki,T Matsumoto,T Naka, EXPERIMENTAL HEMATOLOGY, CARDEN JENNINGS PUBL CO LTD, Vol. 26, No. 8, p. 759-759, 1998/08
  • サイトカインシグナルの負のフィードバック, 藤本穣,楢崎雅司,松本智成,仲哲治, 臨床免疫, (有)科学評論社, Vol. 30, No. 6, p. 788-795, 1998/06
  • STAT-induced STAT inhibitor-1 (SSI-1), 藤本穣,楢崎雅司,仲哲治, Annual review 免疫 1999, Vol. 1999, 1998
  • IL-6-induced tyrosine phosphorylation of Vav., IS Lee,Y Liu,M Narazaki,T Kishimoto,T Taga, TISSUE ANTIGENS, WILEY, Vol. 48, No. 4-II, p. CR209-CR209, 1996/10
  • Two distinct pathways that mediate gp130-induced cell proliferation; SHP-2-p42/p44 map kinase pathway and state pathway., M Narazaki,K Nakashima,T Kishimoto,T Taga, TISSUE ANTIGENS, WILEY, Vol. 48, No. 4-II, p. CR210-CR210, 1996/10
  • IL-6受容体から遺伝子発現までのシグナル伝達経路, 楢崎雅司, 治療学, Vol. 30, p. 14-18, 1996
  • gp130を介するシグナル伝達経路, 楢崎雅司, Annual review 免疫 1997, p. 259-268, 1996
  • THE MOLECULAR-BIOLOGY OF INTERLEUKIN-6 AND ITS RECEPTOR, T KISHIMOTO,M HIBI,M MURAKAMI,M NARAZAKI,M SAITO,T TAGA, CIBA FOUNDATION SYMPOSIA, JOHN WILEY & SONS LTD, Vol. 167, p. 5-23, 1992
  • IL-6レセプターとIL-6シグナル伝達蛋白質gp130の分子構造と機能, 村上正晃,楢崎雅司,斉藤幹良,田賀哲也,日比正彦, 代謝, Vol. 28, p. 101-113, 1991

Publications

  • 内科学書, 楢崎雅司, 中山書店, ISBN:9784521747491, 2019/08
  • 今日の疾患辞典 Current Decision Support, 楢崎雅司, 2019
  • 通訳者のための医療の知識, 楢崎雅司, 保育社, ISBN:9784586085927, 2018/04
  • 免疫学コア講義 (改訂4版), 楢崎雅司, 南山堂, ISBN:9784525167547, 2017/11
  • 関節リウマチの免疫異常と炎症の背景, 楢崎雅司, CLINICIAN(エーザイ株式会社), 2017/07
  • 腸内細菌と関節リウマチ, 楢崎雅司, CLINICIAN(エーザイ株式会社), 2016/10
  • リウマチ・膠原病診療ハイグレード 分子標的/Bio時代のリウマチ・膠原病治療ストラテジー「悪性関節リウマチとリウマトイド血管炎」, 楢崎雅司, 文光堂, ISBN:9784830620584, 2015/10
  • Molecular biology of B cells, Tanaka T,Narazaki M,Kishimoto T, Elsevier Academic Press, ISBN:9780123979339, 2015
  • リウマチ病セミナー XXV, 楢崎雅司, 永井書店, 2014/12
  • Molecular Biology of B cell, Second Edition. Anti-interleukin-6 receptor antibody therapy against autoimmune inflammatory diseases., Tanaka T,Narazaki M,Kishimoto T, Edited by T. Honjo, F. Alt, A. Radbruch, M. Reth. Elseviser., 2014/08
  • Encyclopedia of Medical Immunology "Autoimmune diseases", Tanaka T,Narazaki M,Kishimoto T, Springer Reference, ISBN:9780387848273, 2014
  • Interleukin-6 : genetics, clinical applications and role in disease, Tanaka T,Ogata A,Shima Y,Narazaki M,Kumanogoh A,Kishimoto T, Nova Science, ISBN:9781624175923, 2013/05/13
  • 免疫学コア講義(改訂3版), 楢崎雅司, 南山堂, ISBN:9784525167530, 2012/10
  • Basophil granulocytes, Tanaka T,Hirano T,Kawai M,Arimitsu J,Hagihara K,Ogawa M,Kuwahara K,Shima Y,Narazaki M,Ogata A,Kawase I, Nova Science Publishers, ISBN:9781607417972, 2010
  • Cytokine inhibitors, Naka T,Narazaki M,Kishimoto T, Marcel Dekker, ISBN:0824704347, 2001
  • Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996, Lee IS,Liu Y,Narazaki M,Kishimoto T,Taga T, Garland Pub., Inc, ISBN:0815327455, 1998
  • リンパ球機能検索法, 楢崎雅司, 中外医学社, ISBN:4498025180, 1994/11/11
  • Guidebook to cytokines and their receptors, Narazaki M,Kishimoto T, Oxford University Press, ISBN:0198599471, 1994

Industrial Property Rights

  • Induced internalization of surface receptors, Tosato,Giovanna, Narazaki,Masashi, 特許8420620, 登録日:2009/01/23

Presentations

  • Antigen-specific maturation of anti-nuclear antibodies in systemic lupus erythematosus, Shuhei Sakakibara,Kazuya Takeda,Teruhito Yasui,Masashi Narazaki,Toshio Tanaka,Hitoshi Kikutani, 2015/11
  • Optimization of Treatment Intervals of Tocilizumab and Golimumab By Measuring Serum Trough Levels in Rheumatoid Arthritis Patients, Yoshinobu Matsuura,Masashi Narazaki,Masayuki Nishide,Yasuhiro Kato,Hideki Yorifuji,Toru Hirano,Yoshihito Shima,Toshio Tanaka,Atsushi Ogata,Atsushi Kumanogoh, ARTHRITIS & RHEUMATOLOGY, 2015/10
  • 生物学的製剤血中トラフ濃度測定による投与間隔の最適化の検討, 松浦良信,楢崎雅司,依藤秀樹,加藤保宏,西出真之,菱谷好洋,平野 亨,嶋 良仁,仲 哲治,田中敏郎,緒方 篤,熊ノ郷淳, 第59回日本リウマチ学会 名古屋
  • INCREASED SOLUBLE SEMAPHORIN 4D IN RHEUMATOID ARTHRITIS, Y. Yoshida,A. Ogata,T. Tomita,S. Kang,T. Hirano,Y. Shima,M. Narazaki,T. Tanaka,A. Kumanogoh, ANNALS OF THE RHEUMATIC DISEASES, 2014/06
  • 特発性非特異的間質性肺炎診断における抗Mx1抗体の有用性, 濱野 芳匡,木田 博,森島 淳仁,平野 亨,楢崎 雅司,嶋 良仁,緒方 篤,立花 功,田中 敏郎,熊ノ郷 淳, 日本リウマチ学会総会・学術集会プログラム・抄録集, 2014/03
  • SLEの新しい分類基準, 楢崎雅司, 第25回中之島リウマチセミナー, 2013/12/21
  • 自己抗体 特発性非特異的間質性肺炎(Idiopathic NSIP)における疾患特異的自己抗体検索, 2013/03
  • 大阪大学における生物学的製剤の使用経験, 菱谷好洋,平野亨,嶋良仁,萩原圭祐,楢崎雅司,緒方篤,蛯名耕介,史賢林,椚座康夫,冨田哲也,田中敏郎,熊ノ郷淳, 第56回日本リウマチ学会 東京, 2012/03/19
  • SSI‐1はIRS‐1のリン酸化を抑制することにより,insulinシグナル伝達を阻害する, 川添嘉徳,仲哲治,藤本穣,神崎秀嗣,森田善昭,奥村晃市,楢崎雅司,蕃良静男,岸本忠三, 日本免疫学会総会・学術集会記録, 2000/09/26
  • SSI/SOCS‐1によるTNFαシグナル伝達の抑制, 森田善昭,藤本穣,川添嘉徳,楢崎雅司,中川れい子,立石明広,奥村晃市,福山英啓,岸本忠三, 日本免疫学会総会・学術集会記録, 1999/10/30
  • SSI‐1トランスジェニックマウスの解析, 藤本穣,仲哲治,中川れい子,川添嘉徳,森田善昭,楢崎雅司,長沢丘司,藤原大美,岸本忠三, 日本免疫学会総会・学術集会記録, 1999/10/30
  • IL-6ファミリーサイトカインにより活性化されるSTAT3セリンキナーゼの解析, 中島欽一,楢崎雅司,松尾律子,田賀哲也, 日本分子生物学会年会プログラム・講演要旨集, 1998/12/01
  • SSI‐1ノックアウトマウスにおけるリンパ球アポトーシスのこう進, 藤本穣,松本智成,楢崎雅司,森田善昭,斉藤博,長沢丘司,仲哲治,岸本忠三, 日本免疫学会総会・学術集会記録, 1998/10
  • SSI‐1(STAT‐induced STAT inhibitor‐1)の機能領域の解析, 楢崎雅司,松本智成,藤本穣,森田善昭,梶田忠宏,吉崎和幸,仲哲治,岸本忠三, 日本免疫学会総会・学術集会記録, 1998/10
  • 線維芽細胞(NIH3T3)におけるInterferon‐γ依存性STAT‐induced STAT Inhibitor‐1(SSI‐1)遺伝子転写促進機構, 森田善昭,斉藤博,藤本穣,松本智成,楢崎雅司,仲哲治,岸本忠三, 日本免疫学会総会・学術集会記録, 1998/10
  • Persistent activation of the STAT1 in rheumatoid synovial fluid cells., A Yokota,M Narazaki,N Murata,T Tanaka,T Kishimoto, ARTHRITIS AND RHEUMATISM, 1997/09
  • TAFRO症候群の血小板減少回復に関する考察:5例の自験例と過去の症例レビュー, 山口勇太,前田悠一,水野裕美子,八木田麻裕,真鍋侑資,森田貴義,西出真之,高松漂太,平野亨,楢崎雅司,熊ノ郷淳, 第63回日本リウマチ学会 京都, 2019
  • 関節リウマチの病態と治療, 楢崎雅司, 平成30年度第5回 箕面市薬剤師会学術研修会, 2018/10/18
  • 免疫の基礎研究と臨床応用〜IL-6の最近の話題も含めて〜, 楢崎雅司, 第62回日本リウマチ学会教育研修会 大阪, 2018
  • 関節リウマチ患者の炎症反応増多に寄与する関節部位の評価〜大阪大学医学部附属病院約3600件のデータ〜, 前田悠一,平野亨,新居卓朗,渡邊あかね,泉真祐子,柴原理志,清水隆,小川恭生,糸田川英里,西出真之,高松漂太,嶋良仁,楢崎雅司,田中敏郎,熊ノ郷淳, 第62回日本リウマチ学会 東京, 2018
  • 最新の関節リウマチ治療ー関節リウマチの内科的治療ー, 楢崎雅司, 読売健康講座, 2016/12/11
  • 最新の関節リウマチ治療ー内科医が診る関節リウマチー, 楢崎雅司, 読売健康講座, 2016/03/06
  • ベーチェット病ぶどう膜炎の治療における不可逆性の影響する因子の検討, 平野 亨,高松漂太,嶋良仁,楢崎雅司,田中敏郎,熊ノ郷淳, 第60回日本リウマチ学会 横浜, 2016
  • The analysis of severity of arthritis in the intestinal microbiota-humanized mice., Maeda Y,Matsushita M,Narazaki M,Saeki Y,Kumanogoh A,Takeda K, ACR 2016, Washington DC, USA., 2016
  • 関節リウマチって何? 〜気になる症状と治療目標〜, 楢崎雅司, なるほど!リウマチ公開講座 in 池田, 2014/06/01
  • 可溶性Sema4Dは関節リウマチ患者の血清、関節液で上昇し、疾患活動性と相関する, 吉田祐志,緒方篤,冨田哲也,平野亨,嶋良仁,楢崎雅司,田中敏郎,熊ノ郷淳, 第58回日本リウマチ学会 東京, 2014
  • 免疫難病におけるIL-6過剰産生の分子機構, 田中敏郎,西岡紘治,平野亨,嶋良仁,楢崎雅司,緒方篤,熊ノ郷淳, 第58回日本リウマチ学会 東京, 2014
  • Soluble Semaphorin 4D in rheumatoid arthritis., Yoshida Y,Ogata A,Tomita T,Hirano T,Shima Y,Narazaki M,Tanaka T,Kumanogoh A, The 58th JCR, international rheumatology symposium. Tokyo, Japan., 2014
  • A case of meningitis with IgG4-producing cells in spinal fluid., Nishide M,Narazaki M,Shen Jiao,Hamano Y,Nakabayashi A,Hirano T,Shima Y,Ogata A,Tanaka T,Kumanogoh A, The 12th International Symposium on Sjogren's Syndrome, Kyoto, Japan., 2013
  • Interleukin-6 targeting strategy for immune-mediated diseases. 15th International congress of Immunology., Tanaka T,Shima Y,Hirano T,Narazaki M,Ogata A,Kumanogoh A,Kishimoto T, The 15th International congress of Immunology, Milano, Italy., 2013
  • Bio-plex cytokine arrayによる肺高血圧症患者におけるサイトカインの病態意義の解析, 萩原圭祐,有光潤介,岸田友紀,中西美保,中林晃彦,森島淳仁,吉田祐志,菱谷好洋,平野亨,嶋良仁,楢崎雅司,緒方篤,田中敏郎,吉川秀樹,熊ノ郷淳, 第56回日本リウマチ学会 東京, 2012
  • 3年間のトシリズマブ投与を行った強皮症患者の病状, 嶋良仁,菱谷好洋,平野亨,楢崎雅司,緒方篤,田中敏郎,熊ノ郷淳, 第56回日本リウマチ学会 東京, 2012
  • Comparison of tolerability between tumor necrosis factor-inhibitors and tocilizumab for the treatment of rheumatoid arthritis., Hishitani Y,Shima Y,Hirano T,Hagihara K,Ebina K,Kunugiza Y,Shi K,Narazaki M,Ogata A,Tomita T,Tanaka T,Kumanogoh A, ACR 2012, Washington DC, USA., 2012
  • Taqman arrayによるTCZ治療患者の病態解析:Fox-P3とCTLA-4は治療後のMMP-3と相関する, 萩原圭祐,森島淳仁,菱谷好洋,河合麻理,有光潤介,平野亨,嶋良仁,楢崎雅司,緒方篤,田中敏郎, 第55回日本リウマチ学会 神戸, 2011
  • Tocilizumabは継続性において優れている, 菱谷好洋,嶋良仁,緒方篤,楢崎雅司,萩原圭祐,平野亨,河合麻理,森島淳仁, 第55回日本リウマチ学会 神戸, 2011
  • HbA1C during humanized anti-intrerleukin-6 receptor antibody, tocilizumab in rheumatoid arthritis with diabetes., Morishima A,Ogata A,Hirano T,Hishitani Y,Hagihara K,Shima Y,Narazaki M,Tanaka T,Kumanogoh A, EULAR 2011, London, UK., 2011
  • Long-term tolerability of tocilizumab for the treatment of rheumatoid arthritis., Hishitani Y,Hirano T,Shima Y,Ogata A,Narazaki M,Hagihara K,Tanaka T, ACR 2011, Chicago, USA., 2011
  • TocilizumabのHbA1C改善効果について, 森島淳仁,緒方篤,萩原圭祐,河合麻理,桑原裕祐,有光潤介,石井泰子,平野亨,嶋良仁,楢崎雅司,田中敏郎, 第54回日本リウマチ学会 神戸, 2010
  • 脾腫を伴った関節リウマチ患者ではトシリズマブの効果が減弱する, 河合麻理,楢崎雅司,森島淳仁,桑原裕祐,石井泰子,平野亨,萩原圭祐,嶋良仁,緒方篤,川瀬一郎,田中敏郎, 第54回日本リウマチ学会 神戸, 2010
  • ヒト化抗IL-6受容体抗体(トシリズマブ)による強皮症治療の試み, 嶋良仁,桑原裕祐,河合麻理,平野亨,森島淳仁,石井泰子,有光潤介,萩原圭祐,楢崎雅司,緒方篤,田中敏郎, 第54回日本リウマチ学会 神戸, 2010
  • サイトカイン網羅解析によるレイノー合併肺高血圧患者へのボセンタン多様性効果の検討, 萩原圭祐,森島淳仁,河合麻理,桑原裕祐,有光潤介,石井泰子,平野亨,嶋良仁,楢崎雅司,緒方篤,田中敏郎, 第54回日本リウマチ学会 神戸, 2010
  • Insufficient effect of tocilizumab on the patients with rheumatoid arthritis who have splenomegaly., Narazaki M,Kawai M,Morishima A,Kuwahara Y,Ishii T,Hirano T,Hagihara K,Shima Y,Ogata A,Kishimoto,Tanaka T, EULAR 2010, Rome, Italy., 2010
  • Tocilizumab does not inhibit interferon synthesis which is a key step of anti-mycobacterial host defenses., Ogata A,Mori M,Hashimoto S,Kawai M,Morishima A,Kuwahara Y,Ogawa M,Hirano T,Ishii T,Arimitsu J,Hagihara K,Shima Y,Narazaki M,Kishimoto T,Tanaka T, EULAR 2010, Rome, Italy., 2010
  • Analysis of effect of bosentan on Raynaud's phenomenon in connective tissue disease-related PAH patients using a Bio-Plex cytokine array., Hagihara K,Murota H,Sakata Y,Morishima A,Kawai M,Arimitsu J,Ishii T,Hirano T,Shima Y,Narazaki M,Ogata A,Tanaka T, EULAR 2010, Rome, Italy., 2010
  • ベーチェット病に対するインフリキシマブ投与継続の効果, 平野亨,河合麻理,有光潤介,桑原裕祐,萩原圭祐,楢崎雅司,嶋良仁,緒方篤,田中敏郎, 第53回日本リウマチ学会 東京, 2009
  • Ligands for scavenger receptor identified as inducers of Neuropilin-1 internalization and functional inhibition of VEGF165 and Sema3A., Narazaki M,Segarra M,Tanaka T,Tosato G, Keystone Symposium, Big Sky, MO, USA., 2009
  • IL-6阻害治療の転写調節レベルでの作用機序ーヒトC反応性タンパク質(CRP)と血清アミロイドA(SSA)の転写調節機序の解析結果を踏まえて, 萩原圭祐,河合麻理,桑原裕祐,平野亨,嶋良仁,楢崎雅司,緒方篤,田中敏郎,川瀬一郎,吉崎和幸, 第52回日本リウマチ学会 札幌, 2008
  • ベーチェット病に対するインフリキシマブ投与の早期効果, 平野亨,河合麻理,桑原裕祐,有光潤介,萩原圭祐,嶋良仁,楢崎雅司,緒方篤,田中敏郎,吉崎和幸,川瀬一郎, 第52回日本リウマチ学会 札幌, 2008
  • SSI/SOCS-1 suppressed TNFalpha-induced cell death in fibroblast. 91st Annual Meeting of the American Association for Cancer Research., Naka T,Morita Y,Fujimoto M,Kawazoe Y,Nakagawa R,Narazaki M,Tateishi A,Fukuyama H,Nagata S,Kishimoto T, The 91st Annual Meeting of the American Association for Cancer Research. San Francisco, USA., 2000
  • Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus., Aoki Y,Narazaki M,Kishimoto T,Tosato G, The 42nd Annual Meeting of the American-Society-of-Hematology. San Francisco, USA., 2000
  • SCID-like lymphocyte decrease in SSI-1/SOCS-1/JAB transgenic mice., Fujimoto M,Naka T,Nakagawa R,Tateishi A,Kawazoe Y,Morita Y,Narazaki M,Fujiwara H,Nagasawa T,Kishimoto T, The 7th Annual Conference of the International Cytokine Society. Hilton Head, USA., 1999
  • SSI/SOCS family proteins are involved in the negative regulation for various signal transduction pathway., Kawazoe Y,Naka T,Okumura K,Fujimoto M,Narazaki M,Morita Y,Nakagawa R,Kishimoto T, The 7th Annual Conference of the International Cytokine Society. Hilton Head USA., 1999
  • SSI-1 (STAT-induced STAT inhibitor-1) の機能領域の解析, 楢崎雅司,松本智成,藤本穣,森田善昭,梶田忠宏,吉崎和幸,仲哲治,岸本忠三, 第28回日本免疫学会 神戸, 1998
  • サイトカイン信号ネガティブフィードバック分子SSI-1による信号伝達抑制機構の解析, 楢崎雅司,仲哲治,松本智成,源誠二郎,池亀和博,山本浩靖,梶田忠宏,吉崎和幸,岸本忠三, 第27回日本免疫学会 札幌, 1997
  • Negative regulation of cytokine signals by STAT-induced STAT-inhibitor-1 (SSI-1)., Kishimoto T,Narazaki M,Matsumoto T,Naka T, International society for experimental hematology. Cannes, France., 1997
  • Structure and function of a new STAT-induced STAT inhibitor., Naka T,Narazaki M,Hirata M,Matsumoto T,Minamoto S,Aono A,Nishimoto N,Kajita T,Taga T,Yoshizaki K,Akira S,Kishimoto T, The 5th Annual Conference of the International Cytokine Society. Lake Tahoe, USA., 1997
  • サイトカイン共通信号伝達分子gp130を介して細胞増殖にかかわるふたつの信号伝達経路, 楢崎雅司,中島欽一,岸本忠三,田賀哲也, 第26回日本免疫学会 横浜, 1996
  • IL-6-induced tyrosine phosphorylation of Vav., Lee IS,Liu Y,Narazaki M,Kishimoto T,Taga T, The 6th International Workshop on Human Leukocyte Differentiation Antigens. Kobe, Japan., 1996
  • Requirement of STAT3 to a box3-containing region of GP130 by activation of either JAK1, JAK2, or TYK2 that is associated with GP130 at a BOX1-containing region., Narazaki M,Kumanogoh A,Inoue M,Akira S,Nagata S,Yasukawa K,Krolewski J,Kishimoto T,Taga T, he 9th International Congress of Immunology. San Francisco, USA., 1995
  • IL-6-induced growth and differentiation signals are mediated by distinct regions of the cytoplasmic domain of the signal transducer gp130., Kumanogoh A,Saito M,Narazaki M,Yoshida K,Kishimoto T,Taga T, The 9th International Congress of Immunology. San Francisco, USA., 1995
  • The molecular biology of interleukin 6 and its receptor., Kishimoto T,Hibi M,Murakami M,Narazaki M,Saito M,Taga T, Ciba Foundation Symposium. London, UK., 1991

Committee Memberships

  • 日本リウマチ学会, 生涯教育委員, 2019/04 - Present
  • 大阪・奈良・和歌山地区日本リウマチ財団研修会, 世話人, 2018/04 - Present
  • 日本リウマチ学会, 評議員, 2010/04 - Present